Tech Company Inital Public Offerings
Beam Therapeutics IPO
Beam Therapeutics was acquired by . Shares were listed on 2/6/2020.
Transaction Overview
Company Name
Announced On
2/6/2020
Transaction Type
IPO
Amount
$180,000,000
Proceeds Purpose
Use of proceeds for the Beam Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
26 Landsdowne St. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Evans
Chief Scientific Officer
Giuseppe Ciaramella
Co-Founder
Keith Joung
Co-Founder
David Liu
Co-Founder
Feng Zhang
Vice President
Francine Gregoire
Vice President
Dana Levasseur
VP - Bus. Development
Courtney Wallace
VP - Finance
Suzanne Fleming
Browse more venture capital transactions:
Prev: 2/6/2020: A.Team venture capital transaction
Next: 2/6/2020: Deliverr venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs